AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04608500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 minocycline foam 1.5%
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study NCT04608500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study NCT03716856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study NCT03716856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 aqueous suspension
Description: 300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: 400 mg (2 capsules of 200 mg each) taken orally x 1 dose
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
Study NCT02674867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Study NCT03382535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice therapy
Description: Voice therapy with direct and indirect therapy elements.
Study NCT04324021 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Emapalumab
Description: I.v. infusion every third day
Study NCT04324021 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Daily i.v. infusion
Study NCT03382535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy with carryover strategies
Description: Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
Study NCT03382535 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
Study NCT05062226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU/TYR GMP Protein Substitute
Description: After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: 1% administered topically
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: 1% administered topically
Study NCT02695745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 1% administered topically
Study NCT03666923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 1
Description: single intravitreal injection of THR-687 dose level 1
Study NCT03666923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 2
Description: single intravitreal injection of THR-687 dose level 2
Study NCT03666923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 3
Description: single intravitreal injection of THR-687 dose level 3
Study NCT04148950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Study NCT04148950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Study NCT03216499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03216499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03216499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT00004126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00004126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00486525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: Patients will undergo yoga therapy
Study NCT03169088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching procedure
Description: In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers
Study NCT03649997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
Study NCT03265132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anakinra
Description: sub cutaneous injection
Study NCT03265132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sub cutaneous injection
Study NCT01407874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.
Study NCT01407874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulodesine (BCX4208) 5 mg
Description: Oral dose administered daily for 84 days.
Study NCT01407874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulodesine (BCX4208) 10 mg
Description: Oral dose administered daily for 84 days.
Study NCT02833727 — intervention group
Intervention type: OTHER
Intervention: Smoking
Description: Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
Study NCT03645161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rat and mouse skin test
Description: Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
Study NCT03420040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QS-M Needle Free Injector
Description: The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
Study NCT03420040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glargine pen
Description: The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
Study NCT04148950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Study NCT04148950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Study NCT01157507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical injection of Botulinum A Toxin
Description: One treatment, 100 U vials diluted in 10 ml normal saline
Study NCT01157507 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bladder overdistension
Description: Bladder overdistension
Study NCT01157507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single injection of placebo
Study NCT01170182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Delayed Release Capsules 40 mg
Study NCT01170182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec® 40 mg
Description: Prilosec® 40 mg
Study NCT03632278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness psychoeducation Programme
Description: A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties.
Study NCT02451410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity
Description: The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
Study NCT03562039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-MIST
Description: minimal invasive surgical technique without thorough removal of granulation tissue
Study NCT03562039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-MIST
Description: minimal invasive surgical technique without thorough removal of granulation tissue
Study NCT04375488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
Study NCT04375488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
Study NCT02385266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
Study NCT02385266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for D-cycloserine)
Description: Lactose filled capsules to mimic DCS 200mg capsules
Study NCT04782856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: levothyroxine sodium tablet for oral use
Study NCT04782856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine sodium tablet for oral use
Study NCT04782856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Liothyronine sodium tablets for oral use treatment of hypothyroidism
Study NCT04782856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: inert sugar tablets for oral use blinding for treatment of hypothyroidism
Study NCT00112658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT01192581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
Study NCT01192581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
Study NCT00112658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT00112658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00112658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00112658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02539381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Formal Perimetry (Goldman or Octopus visual Field)
Study NCT02539381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Albert's visual inattention test
Study NCT02539381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Star cancellation visual inattention test
Study NCT02539381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual field assessment to confrontation
Study NCT02539381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual inattention assessment to bilateral stimuli
Study NCT02539381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital tumbling E visual accuity assessment
Study NCT02539381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital visual field assessment
Study NCT02539381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital line crossing assessment
Study NCT02539381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital shape cancellation assessment
Study NCT02564614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7070179
Description: RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
Study NCT02469428 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean air
Description: Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
Study NCT02469428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
Study NCT01678963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine lactate
Description: Ophthalmic solution 0.2%
Study NCT01678963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Ophthalmic solution vehicle control
Study NCT04369794 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: 0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
Study NCT04369794 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline in the same volume as the BCG vaccine in a single dose
Study NCT00729729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PCA
Description: Placebo tablet, once
Study NCT00872859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Dermal Matrix substitute
Description: Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
Study NCT01192581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
Study NCT03520842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO
Study NCT03520842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03520842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT03773510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin discontinuation
Description: Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin.
Study NCT03773510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin continuation
Description: Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
Study NCT02981745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-1530
Description: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
Study NCT02961231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 2p+1
Description: introduction of PCV in a reduced dosing 2p+1 schedule
Study NCT02961231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 3p+0
Description: introduction of PCV in a reduced dosing 3p+0 schedule
Study NCT02961231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 1p+1
Description: introduction of PCV in a reduced dosing 1p+1 schedule
Study NCT02961231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 0p+1
Description: introduction of PCV in a reduced dosing 0p+1 schedule
Study NCT00431132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 10 mcg
Description: Tablets, administered intravaginally twice weekly
Study NCT02015858 — intervention group
Intervention type: PROCEDURE
Intervention: Chest drain withdrawal
Study NCT02015858 — intervention group
Intervention type: DEVICE
Intervention: Pain Monitor
Study NCT02014753 — intervention group
Intervention type: DEVICE
Intervention: cobalt-chromium everolimus-eluting stent (CoCr-EES)
Study NCT01672827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
Study NCT01410331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(4 mg) or placebo/8 injections
Description: 4 mg of JVS-100 or placebo delivered in 8 injections
Study NCT01410331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(8 mg) or placebo/8 injections
Description: 8 mg of JVS-100 or placebo delivered in 8 injections
Study NCT01410331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(8 mg) or placebo/16 injections
Description: 8 mg of JVS-100 or placebo delivered in 16 injections
Study NCT00729729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA
Description: PO, 700mg, once
Study NCT00729729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA
Description: PO, 1000mg, once
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Manual Muscle Test
Description: Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
Study NCT00545103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered Once Daily (QD)
Study NCT01953913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Patient will receive afatinib once daily
Study NCT01410331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(16 mg) or placebo/16 injections
Description: 16 mg of JVS-100 or placebo delivered in 16 injections
Study NCT05243199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
Study NCT05243199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
Study NCT02394457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: Intravenous Drug Infusion over 1 hour and a half
Study NCT02394457 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
Study NCT02778594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: nebicapone 50 mg tablets; oral use
Study NCT02778594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebicapone matching placebo tablets